axinn



2 MIN READ

June 28, 2024, 11:30 AM By: Aaron Z. Savit, PhD, Ian Swan

For forty years, *Chevron* has put a thumb on the scales in favor of the executive agencies whenever their decisions were challenged in court. Now, the <u>Supreme Court has overturned that longstanding precedent</u>, issuing its opinion in the two cases that will define judicial deference to executive agencies going forward. In today's decision in *Loper Bright* and *Relentless*, the Supreme Court scuttled *Chevron*, holding that the precedent could not be squared with the Administrative Procedure Act (APA), which requires that courts decide "all relevant questions of law' arising on review of agency action." The Court criticized the underlying reasoning for *Chevron*, which assumed that any statutory ambiguities implicitly delegate interpretive authority to Executive Agencies. The Court also determined that common justifications for agency deference, such as agency expertise or the promotion of uniformity in the law, could not displace the judiciary's interpretive role. Importantly, the Court confirmed that holdings in previous cases decided under *Chevron* will remain in effect.

As we explained more fully in another article, those two cases, *Loper Bright Enterprises v. Raimondo* and *Relentless, Inc. v. Department of Commerce*, have broadly similar facts. Both cases involve the application of the *Chevron* doctrine to fisheries rules requiring that fishing vessels pay for fees associated with on-board monitors. Those rules were upheld by lower courts, and the Supreme Court granted certiorari to consider "[w]hether the Court should overrule *Chevron* or at least clarify that statutory silence concerning controversial powers

expressly but narrowly granted elsewhere in the statute does not constitute an ambiguity requiring deference to the agency."

In recent years, the Supreme Court has not directly cited *Chevron* in multiple cases regarding agency deference. See e.g., Am. Hosp. Ass'n v. Becerra, 142 S. Ct. 1896 (2022). As such, many observers expected that the Court would take this opportunity to either narrow *Chevron* deference or replace it entirely. Now that *Chevron* has been definitively overturned, FDA will likely find its determinations are more frequently challenged in court. This will lead to greater uncertainty for regulated industry and may ultimately affect the Agency's approach to its decision-making processes generally, including potentially slowing down the speed with which FDA renders its decisions.



Related People



Aaron Z. Savit, PhD



Related Services

Intellectual Property

To subscribe to our publications, click here.

TAGS

regulatory

News & Insights

- American Bar Association 2025 Asia-Pacific Conference SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
 SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Corporate Counsel Retreat 2025
 SPONSORSHIP ANTITRUST
- Forecasting Health Care Antitrust Under a Second Trump Administration
 PODCAST ANTITRUST
- GCR 100 2025 Ranks Axinn Antitrust Group in Top Categories

AWARDS & RECOGNITIONS ANTITRUST

- What Trump's FTC Picks Mean for Bio-Pharma Dealmaking and PBMs
 MEDIA MENTIONS ANTITRUST
- Capitol Forum Health Care Competition Conference 2024
 SPEAKING ENGAGEMENT ANTITRUST
- Ethical Considerations for Cybersecurity, IP Transactions and Avoiding USPTO Sanctions (EIP241212)

SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY

Albertsons Ends Merger Deal, Accuses Kroger of 'Self-Serving Conduct'
 MEDIA MENTIONS ANTITRUST

© 2024 Axinn, Veltrop & Harkrider LLP. All Rights Reserved